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Abstract. Measuring baseline levels of adherence and identifying risk factors for non-adherence are important steps
before the introduction of new antimalarials. In Mbarara in southwestern Uganda, we assessed adherence to artemether-
lumefantrine (Coartem) in its latest World Health Organization blister formulation. Patients with uncomplicated
Plasmodium falciparum malaria were prescribed artemether-lumefantrine and received an explanation of how to take
the following five doses at home. A tablet count was made and a questionnaire was completed during a home visit.
Among 210 analyzable patients, 21 (10.0%) were definitely or probably non-adherent, whereas 189 (90.0%) were
probably adherent. Age group was not associated with adherence. Lack of formal education was the only factor
associated with non-adherence after controlling for confounders (odds ratio  3.1, 95% confidence interval [CI] 
1.1−9.7). Mean lumefantrine blood levels were lower among non-adherent (n 16) (2.76 g/mL, 95% CI  1.06−4.45)
than among adherent (n  171) (3.19 g/mL, 95% CI  2.84−3.54) patients, but this difference was not statistically
significant. The high adherence to artemether-lumefantrine found in our study suggest that this drug is likely to be very
effective in Mbarara provided that patients receive clear dosage explanations.
INTRODUCTION
Throughout Africa, increasing resistance of Plasmodium
falciparum to common antimalarials poses an important ob-
stacle for malaria control. The introduction of artemisinin-
based combination therapy (ACT) has been suggested to re-
place ineffective treatments.1,2 However, for the successful
deployment of ACT, the issue of patients’ adherence needs to
be considered.3 Poor levels of adherence are likely to de-
crease cure rates, and exposure of the parasite to sub-
therapeutic drug levels may favor the development of resis-
tance.1 Measuring baseline levels of adherence and identify-
ing possible risk factors for non-adherence are therefore
important steps before the introduction of ACT. Such data
should permit rational recommendations to be made that can
increase the probability of correct use of the treatment. To
date, there is little evidence concerning adherence to ACT in
Africa.4,5
Mbarara, a town in southwestern Uganda situated in an
area of mesoendemic malaria, has levels of P. falciparum re-
sistance to both chloroquine (CQ) and sulfadoxine-
pyrimethamine (SP) greater than 30%.6,7 In the short term, if
not currently, the first-line treatment for P. falciparum ma-
laria in Uganda (an association of CQ and SP) is likely to be
ineffective.8 Coartem (a co-formulation of artemether and
lumefantrine) has an excellent efficacy and tolerability pro-
file,9–11 and could be a suitable alternative in Mbarara and
other areas with similarly high levels of resistance, provided
that the drug is taken as prescribed. However, sub-optimal
adherence to artemether-lumefantrine may well represent an
important obstacle to its use: the recommended method of
intake is two daily doses for three days, respecting a strict
eight-hour interval between the first and the second dose;
also, each dose should be accompanied by a fatty meal so as
to maximize lumefantrine absorption. We report a study con-
ducted in Mbarara in 2002 with the main objectives of mea-
suring overall adherence of patients with malaria to a six-dose
artemether-lumefantrine regimen when given in an outpa-
tient setting, and identifying risk factors for poor adherence.
MATERIALS AND METHODS
Study site and population. Mbarara District, situated in
southwestern Uganda, is an area of year-round malaria trans-
mission. Malaria is a major health problem, accounting for
approximately one-third of all Outpatient Department
(OPD) consultations at the regional referral hospital,
Mbarara University Teaching Hospital. Plasmodium falci-
parum is present in more than 95% of all malaria infections.
Patients resident in Mbarara Municipality, a semi-urban area
with a population of 69,200 (2002 census), were screened at
the hospital OPD and surrounding dispensaries. The study
was reviewed and approved by the Mbarara University of
Science and Technology Institutional Ethical Committee, and
by the Uganda National Council of Science and Technology.
Study subjects and sample size. Patients were recruited into
the study if they met the following inclusion criteria: reported
fever within the last 48 hours and/or an axillary temperature
 37.5°C, a weight 10 kg, no household member previously
participating in the study, and a positive malaria blood smear
containing P. falciparum with no signs of complicated malaria
or other severe disease. To compare adherence according to
differences in drug-taking behavior, patients were recruited in
three age groups: < 5 years old (young children), 5−14 years
old (school age children), and  15 years old (independent
adults). Assuming an adherence of 80%, a precision of 10%,
a type 1 error of 5% and a 20% loss to follow-up, 75 patients
were needed in each age group.
Study procedures. Baseline data concerning history of the
disease episode and demographic information (including the
patient’s address) were collected. A simple clinical examina-
tion was performed. Patients meeting inclusion criteria re-
ceived an explanation that they were being offered a new
drug for the treatment of malaria that was different from the
antimalarials currently on the market, and were asked to pro-
vide signed written consent to receive the drug. They were
given standardized instructions by a nurse on how to take the
artemether-lumefantrine regimen, specifically that the second
dose was to be taken eight hours after the first dose, then two
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doses per day in the morning and evening for the following
two days; that all doses should be taken with food, preferably
containing fat or oil; and that vomited doses should be re-
peated if vomiting occurred within 30 minutes of taking the
dose, with the option of the patient coming to the clinic to
collect a replacement dose. Patients received the latest World
Health Organization (WHO) weight-specific artemether-
lumefantrine (Coartem) blister packs (10.−14.9 kg: 1 tablet
per dose; 15.0−24.9 kg: 2 tablets; 25.0−34.9 kg: 3 tablets;  35
kg: 4 tablets; Novartis Pharma AG, Basel, Switzerland). The
packs contain pictorial instructions on the regimen schedule
(Figure 1), and the blister is uniquely sealed so as to discour-
age private sale. All patients were given the first dose of
artemether-lumefantrine in the clinic with milk and ground-
nuts and observed for 30 minutes. Patients were not aware on
leaving the clinic that they were going to be visited at home or
that they would be assessed for adherence. Field teams con-
sisting of a field worker and a nurse traced the patient’s home
on the day after the regimen should have been completed
(day 3). They introduced themselves as part of the team that
had provided the patient with treatment for malaria two days
earlier and asked the participants to respond to questions
relating to how they took the medicine and to give blood
samples for a blood smear and lumefantrine analysis. Written
informed consent was then obtained from adult patients and
from caregivers if the patient was less than 18 years old. A
pre-piloted questionnaire was used to assess adherence. Re-
spondents were patients themselves if  15 years old or their
caregivers if younger. An open question was provided to de-
termine how the regimen was taken. This was followed by a
structured interview concerning the time and method of tak-
ing each dose. Basic sociodemographic information was also
collected (household size, level of education of respondent,
number of children cared for by respondent). The blister pack
was then examined, if available, for remaining tablets. A cap-
illary blood smear for microscopic examination and a 4-mL
venous sample for quantification of blood lumefantrine levels
were also collected.
Definition of adherence. Patients were classified according
to the following categories of adherence, which combine find-
ings from the blister pack check and the questionnaire. Pa-
tients who had tablets remaining in the blister pack were
classified as definitely non-adherent. When the blister pack
was either missing or empty, patients with information on all
six doses were classified as either probably non-adherent
when the patient did not report taking all doses at the correct
time on the correct day and in the correct amount, or as
probably adherent when the patient reported taking all doses
at the correct time on the correct day and in the correct
amount. Patients who vomited one or more doses were ex-
cluded from the analysis.
Laboratory methods. Slides were stained with Giemsa and
read for species and parasitemia by an experienced techni-
cian. Parasitemias were calculated against 200−500 leukocytes
according to the formula: parasitemia (/L)  number of
parasites × 8,000/number of leukocytes. A slide was consid-
ered negative after 200 high-power fields had been examined.
Venous blood samples were frozen at −80°C and shipped to
Novartis Pharma SAS Bioanalytics and Pharmacokinetics
(Rueil-Malmaison, France) where lumefantrine plasma con-
centrations were analyzed blindly by means of a previously
described high-performance liquid chromatography method12
adapted for use of mass spectrometry rather than ultraviolet
detection.
Statistical analysis. Data were entered on Epi-Info version
6.04 (Centers for Disease Control and Prevention, Atlanta,
GA) and analyzed using SPSS version 10.0.5 (SPSS, Inc., Chi-
cago, IL) and Stata version 8.2 (Stata Corporation, College
Station, TX) software. The three categories of adherence
were presented as proportions and compared among age
groups using a chi-square test. The association between ad-
herence and several exposure variables (age, educational
level of the respondent, number of children cared for by the
respondent, history of antimalarial intake, presence/absence
of fever on presentation) was first analyzed in a univariate
model using a chi-square test. For this purpose, the two
groups probably non-adherent and definitely non-adherent
were combined into a non-adherent group so as to increase
statistical power. Exposure variables were categorized as fol-
lows: axillary temperature as fever if 37.5°C; parasitemia as
low (< 500 parasites/L), medium (500−100,000 parasites/L)
or high (> 100,000 parasites/L); household size as < 5 per-
sons and 6 persons; and number of children cared for by the
respondent as < 2 and  3. Explanatory variables associated
FIGURE 1. Pictorial instructions on the World Health Organization artemether-lumefantrine (Coartem) blister pack (example for weight
range  10−14 kg).
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with the outcome at the P < 0.2 level were entered in a mul-
tivariate logistic regression model. Lumefantrine plasma con-
centrations were described by age group and category of ad-
herence as means with corresponding standard deviations.
The association between day 3 lumefantrine plasma concen-
trations and the same explanatory variables as mentioned ear-
lier was first analyzed by a univariate t-test adjusting for un-
equal variances. Variables associated with lumefantrine at the
P < 0.2 level were then entered into a multivariate analysis of
variance (ANOVA) regression model and validated through
Barlett’s test for the equal variance assumption. Agreement
(kappa statistic) between verbal responses and the tablet
count provided an estimation of the reliability of the ques-
tionnaire. A kappa coefficient > 0.80 was considered as a
measure of very good reliability.
RESULTS
General characteristics of the sample. Between July and
October 2002, a total of 1,277 patients were screened, of
whom 235 (18.4%) were recruited into the study. The vast
majority of infections (225 of 235, 95.7%) were pure P. falci-
parum. Eighty-three patients were in the < 5 years old age
group, 78 in the 5−14 years old group, and 74 in the 15 years
old age group. These groups were significantly different re-
garding sex distribution, presence of fever at examination,
and initial level of parasitemia (Table 1). Forty-four percent
of patients reported taking at least one dose of an antimalarial
before attending the OPD. Seventeen patients could not be
traced, leaving data from 218 home interviews.
Analysis of adherence. Among the 218 patients inter-
viewed, 8 had incomplete data for analysis of adherence due
to failure to give analyzable information concerning the tim-
ing of doses or the number of tablets taken per dose during
the interviews. Of the remaining 210, 15 (7.1%, 95% confi-
dence interval [CI]  4.0−11.5) had tablets remaining in the
blister pack, and were thus classified as definitely non-
adherent; 6 (2.9%, 95% CI  1.0−6.1) reported taking the
regimen in a non-adherent manner and were thus classified as
probably non-adherent; 189 (90.0%, 95% CI  85.1−93.7)
reported taking the regimen in an adherent manner and were
therefore classified as probably adherent. Of the 15 patients
reporting missed doses, 8 (53.3%) missed only one dose. The
most commonly missed dose was the sixth dose (41.7% of the
missed doses). All patients but three children less than five
years old (all with a parasite density < 50 trophozoites/L and
classified as probably adherent) had cleared their parasitemia
on the day of the visit. Age group was not found to be asso-
ciated with adherence (the proportions adherent in each
group were 91.9% (< 5 years old), 89.0% (5−14 years old)
and 88.9% ( 15 years old) (P  0.79). Four variables were
significantly associated (P < 0.20) with being non-adherent in
the univariate analysis: low parasite density (< 500 parasites/
L), absence of splenomegaly, household size < 6, and lack of
formal education in the patient or the caregiver. When fitted
in a multivariate model, only this last variable remained sig-
nificantly associated with the outcome after allowing for po-
tential confounders: among the 21 non-adherent patients, 6
(28.5%) had received no formal education versus 24 (12.7%)
of 189 in the adherent group (P < 0.05; odds ratio 3.1, 95%
CI  1.1−9.7).
Analysis of plasma lumefantrine levels. Measurement of
day 3 plasma lumefantrine was done on 187 patients (12 pa-
tients were traced after day 3, 2 children had failed blood
draws, and 9 did not provide an analyzable sample due to
small volume or accidental hemolysis), of which 16 were in
TABLE 1
Main characteristics of the study subjects
Age group (years)
P*
<5 5–14 15 Total
n % n % n % n %
Inclusion (n  235)
Sex
Male 50 60.2 45 57.7 26 45.1 121 51.5 <0.01
Female 33 39.8 33 42.3 48 64.9 114 48.5
Fever ( 37.5°C)†
Yes 37 44.6 20 25.6 9 12.5 66 28.3 <0.01
No 46 55.4 58 74.4 63 87.5 167 71.7
Parasitemia (/L)
< 500 18 21.7 22 28.9 29 39.7 69 30.0 <0.01
500–100,000 54 65.1 47 61.8 44 60.3 143 62.0
> 100,000 11 13.2 7 9.2 0 0.0 18 8.0
House visit (n  218)
Formal education of
patient or caregiver
None 13 16.5 14 18.7 3 4.7 30 13.7 0.04
At least primary 66 83.5 61 81.3 61 95.3 188 86.3
Household size (n)
0–5 59 74.7 43 57.3 50 78.1 152 69.7 0.01
 6 20 25.3 32 42.7 14 21.9 66 30.3
Children cared for by
respondent (n)
0–2 61 77.2 58 77.3 60 93.8 179 82.1 0.01
 3 18 22.8 17 22.7 4 6.3 39 17.9
* Chi-square for the difference in proportions between the three age groups, for the corresponding variable.
† Two missing values for fever.
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the non-adherent group and 171 in the adherent group. The
median lumefantrine level was 2.45 g/mL (range 
0.06−11.4), with median levels in those less than five years old
significantly lower than in the two other age groups (P < 0.01)
(Figure 2). Wide variations in individual levels were seen in
each category of age. Mean lumefantrine levels were lower in
the non-adherent group (2.76 g/mL, 95% CI  1.06−4.45)
than in the adherent group (3.23 g/mL, 95% CI 
2.87−3.59), but this difference was not statistically significant
(P  0.46). Six variables were significantly associated with a
low plasma lumefantrine concentration after univariate analy-
sis: an age less than 5 years (P < 0.01), pallor (P  0.04),
splenomegaly (P 0.19), abdominal pain (P < 0.01), a history
of jaundice (P  0.02), and a lack of formal education (P <
0.01). After multivariate ANOVA regression, four variables
remained significantly associated with lumefantrine level:
lack of formal education, an age less than 5 years, and history
of jaundice were associated with lower plasma lumefantrine,
whereas abdominal pain was associated with higher lumefan-
trine levels (Table 2).
Validation of the questionnaire. Of the 218 patients visited,
182 (83.5%) had the blister pack available. Of the responses,
97.3% (177 of 182) were concordant (i.e., the patient reported
finishing the treatment course and there were no tablets left
in the blister pack, or the patient reported not finishing the
treatment and there were tablets remaining in the blister
pack). The remaining 2.7% (5 of 182) of responses were dis-
cordant. The kappa coefficient was thus 0.81 (95% CI 
0.54−0.95), thus showing very good agreement between these
two complementary methods of assessing adherence.
DISCUSSION
The high levels of adherence demonstrated in this study are
very encouraging with regard to the feasibility of widespread
introduction of artemether-lumefantrine. Only 7.1% (95%
CI  4.0−11.5) of patients were definitely non-adherent, a
figure lower than that found in two other similar studies con-
ducted in Zambia4 and southern Sudan,5 where 18.3% and
21.2% of the patients were definitely non-adherent to a three-
day regimen of artesunate plus SP and artemether-lume-
fantrine, respectively. However, these latter studies were con-
ducted in complex settings (refugee and internally displaced
populations), which are not easily comparable to our stable
site.
Several factors may have contributed to these high levels of
adherence. The drug used was the latest WHO-approved blis-
ter pack, which contains pictorial instructions on how to take
the drug, a factor that has been shown to improve adher-
ence.13 A detailed verbal explanation was also given with the
drug with clear instructions on how to take the medication, an
intervention shown to contribute to improved adherence.14
The rapid clinical improvement under ACT treatment15 may
also have encouraged patients to complete the regimen, al-
though, conversely, feeling better may have been a reason for
some patients to miss doses on the last day, as was the case in
almost half of the missed doses in our study. The lack of a
relationship between adherence and age group in Mbarara
was an important finding, demonstrating that tablets were
FIGURE 2. Box plots of blood lumefantrine concentrations by age group. Error bars represent the first (lower bar) and third (upper bar)
quartiles. The horizontal lines in the boxes represent the medians.
TABLE 2
Multivariate analysis of variance regression model of the association
of several exposure variables with day 3 plasma lumefan-
trine concentration
Variable P Coefficient 95% confidence interval
No formal education 0.03 −1.01 −1.90–−0.12
Age < 5 years <0.01 −1.46 −2.14–−0.78
History of jaundice <0.01 −2.67 −4.26–−1.08
Abdominal pain 0.01 0.86 0.21–1.51
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well accepted by young children, and that the standard in-
structions given were suitable both for patients and for care-
givers.
An important finding of our study was the association be-
tween education of the patient/caregiver and adherence,
which mirrored results from Zambia.4 Education may have an
effect on the patient/caregiver understanding the instructions
given in the clinic, the quality of the patients’ relationship
with the health care provider, and the ability of the patient to
interpret pictorial instructions on the artemether-lumefan-
trine pack. However, educational attainment is also a proxy
measure for other sociodemographic and economic factors
that may affect adherence, and which were not investigated in
this study. The generally high educational level of the semi-
urban population in Mbarara indicates that in more rural and/
or less educated populations, extra emphasis on appropriate
health education messages would increase the quality of
counseling and promote high levels of adherence.16,17
The main results of the lumefantrine analysis confirm what
has already been described in the literature, although these
findings may not always have a very clear explanation.9,18
First, lumefantrine levels seem to be lower in very young
children, which probably reflects differences in absorption
and metabolism. Second, lumefantrine levels on the day after
completion of treatment vary largely from one individual to
another, even for patients of similar age groups. In our site,
this may have been due to differences in fat intake, one of the
major determinants of lumefantrine absorption, which was
not measured in our study. The fraction of the dose absorbed
is highly variable between patients, and also between doses.18
Lumefantrine levels seven days after the first dose have been
shown to be more closely related to cure rates, and therefore
probably to adherence. We did not re-sample patients on day
7 because the day 3 questionnaire could have encouraged
non-adherent respondents to complete the regimen, thus in-
troducing a bias. In our study, there was some evidence that
non-adherence caused lower day 3 lumefantrine levels, al-
though this association was not statistically significant, prob-
ably due to insufficient power. We had hypothesized that
plasma lumefantrine levels on day 3 would show a correlation
with adherence, i.e., plasma levels would be lower in non-
adherent than in adherent patients. This rational was based
on data showing that the maximum plasma lumefantrine con-
centrations were reached mainly on day 3 after the last dose
of a six-dose regimen given to malaria patients.9,18,19 We as-
sumed, therefore, that lumefantrine levels on day 3 would be
lower, on average, in patients who had failed to take the
complete six doses regimen. Our data proved this to be the
case, although due to the low number of patients in the non-
adherent group, this difference was not statistically signifi-
cant. Further studies including more patients may be neces-
sary to confirm that lumefantrine plasma levels on day 3 can
be used as a surrogative marker of adherence. Young age was
associated with low lumefantrine levels on day 3, an observa-
tion which, as mentioned earlier, may reflect differences in
absorption and metabolism. Lack of education was also asso-
ciated with lower lumefantrine, perhaps an indirect result of
lower adherence. The association between decreased lume-
fantrine plasma concentrations and jaundice could be due to
a reduction of the bioavailability of the drug in patients with
decreased bile production, as has been observed in animal
models (see Discussion section on Ezzet and others19). The
association between increased lumefantrine plasma concen-
trations and abdominal pain is less clear and could be merely
be due to chance. However abdominal pain is a known side
effect associated with the artemether-lumefantrine drug com-
bination,9 and suggests that elevated plasma lumefantrine lev-
els account for this side effect.
The high levels of adherence to artemether-lumefantrine
found in our study suggest that this drug, given in its current
WHO formulation, is likely to be very effective in Mbarara
and in other regions with high levels of resistance to other
antimalarials, provided that clear explanations on how to take
the treatment are given to the patient. Particular attention
should be paid to people with a low level of formal education.
The investment to improve patient adherence should be in-
tegral to the introduction of combination therapy. Consider-
ing issues of adherence whilst introducing ACTs, and moni-
toring adherence after they are deployed, are essential to help
ensure long-term treatment efficacy.
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